Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XBiotech Inc.XBIT · Entity 7044 | Director | June 20, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XBiotech Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2034-06-20 | Direct | 37,500 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 37,500 · Balance 37,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 21, 2024 18:16 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantDirector Stock Option · Derivative | 37,500 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0000950170-24-076082 · ownership.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2034-06-20 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 12:47 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantDirector Stock Option · Derivative | 25,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001209191-23-039579 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-23 Read SEC document |
| June 22, 2022 Filed Jun 27, 2022 21:57 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $5.89 | $0.00 |
DisclosureSEC source: 0001209191-22-039513 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-22 Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 14:55 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-21-042913 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-22 Read SEC document |
| August 27, 2020 Filed Sep 1, 2020 20:06 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001209191-20-048901 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-27 Read SEC document |
| February 12, 2020 Filed Feb 13, 2020 21:52 UTC | XBiotech Inc. XBIT · Entity 7044 | Disposition to issuerCommon Stock | 95,612 | $30.00 | $2,868,360.00 |
DisclosureSEC source: 0001209191-20-009282 · doc4.xml · nonDerivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,388 Read SEC document |
| February 12, 2020 Filed Mar 19, 2020 17:26 UTC Amendment | XBiotech Inc. XBIT · Entity 7044 | Disposition to issuerCommon Stock | 99,757 | $30.00 | $2,992,710.00 |
DisclosureSEC source: 0001209191-20-020219 · doc4a.xml · nonDerivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,243 Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 19:36 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0001209191-19-039652 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-27 Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 19:17 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantStock Option · Derivative | 12,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001209191-18-038904 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:10 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantDirector Stock Option · Derivative | 25,000 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0001209191-18-015100 · doc4.xml · derivative · entry 1 Waldin Jan-Paul · CIK 0001733176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-27 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.